Technologies
Title: | BBV154 - A novel adenovirus vectored, intranasal vaccine for COVID-19 |
Area: | COVID-19 Technology |
Focus Area: | Vaccines, Infectious Diseases |
Status: | Market authorization is received for COVID 19 |
Social Benefits: | Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19. The technology helps for pandemic preparedness |
Developing Agency: | Bharat Biotech, Hyderabad |
Technology Readiness Index: | TRL-9 |
Brief Description
Description : | DBT-BIRAC supported India's first Intranasal vaccine to prevent COVID-19 by Bharat Biotech private limited |